JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$761M |
| 2 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$735M |
| 3 |
Zimmer Biomet
ZBH
|
+$542M |
| 4 |
Amazon
AMZN
|
+$439M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$438M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.01B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$1.11B |
| 3 |
AABA
Altaba Inc
AABA
|
+$699M |
| 4 |
TJX Companies
TJX
|
+$682M |
| 5 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.01% |
| 2 | Financials | 14.82% |
| 3 | Technology | 12.49% |
| 4 | Healthcare | 9.61% |
| 5 | Consumer Discretionary | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2926
CALL
Parker-Hannifin
PH
$123B
| $2.99M | ﹤0.01% |
15,000
-25,000
| -63% | -$4.65M |
2017 Q1
3 quarters
|
|
2927
CALL
Capital One
COF
$119B
| $2.99M | ﹤0.01% |
30,000
| – | – |
2017 Q3
1 quarter
|
|
|
2928
PUT
Capital One
COF
$119B
| $2.99M | ﹤0.01% |
30,000
-46,700
| -61% | -$4.26M |
2017 Q2
2 quarters
|
|
|
LPSN
2929
DELISTED
LivePerson
LPSN
| $2.98M | ﹤0.01% |
17,286
+12,250
| +243% | +$2.29M |
2016 Q3
5 quarters
|
|
2930
PUT
Vertex Pharmaceuticals
VRTX
$128B
| $2.98M | ﹤0.01% |
19,900
-188,600
| -90% | -$27.9M |
2017 Q3
1 quarter
|
|
2931
CALL
Travelers Companies
TRV
$75.2B
| $2.97M | ﹤0.01% |
21,900
-32,700
| -60% | -$4.32M |
2017 Q3
1 quarter
|
|
2932
CALL
Sociedad Química y Minera de Chile
SQM
$18.4B
| $2.97M | ﹤0.01% |
+50,000
| New | +$2.87M |
2017 Q4
0 quarters
|
|
2933
X4 Pharmaceuticals
XFOR
$281M
| $2.97M | ﹤0.01% |
+1,292
| New | +$3.27M |
2017 Q4
0 quarters
|
|
|
AY
2934
DELISTED
Atlantica Sustainable Infrastructure plc Ordinary Shares
AY
| $2.97M | ﹤0.01% |
139,845
+17,451
| +14% | +$381K |
2015 Q3
9 quarters
|
|
|
TSC
2935
DELISTED
TriState Capital Holdings, Inc.
TSC
| $2.97M | ﹤0.01% |
128,942
-117,883
| -48% | -$2.74M |
2014 Q1
15 quarters
|
|
|
ESPR
2936
CALL
DELISTED
Esperion Therapeutics
ESPR
| $2.96M | ﹤0.01% |
+45,000
| New | +$2.42M |
2017 Q4
0 quarters
|
|
|
ESPR
2937
PUT
DELISTED
Esperion Therapeutics
ESPR
| $2.96M | ﹤0.01% |
+45,000
| New | +$2.42M |
2017 Q4
0 quarters
|
|
|
CORE
2938
DELISTED
Core Mark Holding Co., Inc.
CORE
| $2.96M | ﹤0.01% |
93,642
+4,339
| +5% | +$139K |
2013 Q2
18 quarters
|
|
2939
iShares US Home Construction ETF
ITB
$2.34B
| $2.95M | ﹤0.01% |
67,476
-3,281
| -5% | -$133K |
2013 Q2
18 quarters
|
|
2940
CALL
Carnival Corporation Ltd
CCL
$34.7B
| $2.95M | ﹤0.01% |
44,400
| – | – |
2017 Q3
1 quarter
|
|
|
2941
PUT
Carnival Corporation Ltd
CCL
$34.7B
| $2.95M | ﹤0.01% |
44,400
| – | – |
2017 Q3
1 quarter
|
|
|
AFAM
2942
DELISTED
Almost Family Inc
AFAM
| $2.94M | ﹤0.01% |
53,184
+52,589
| +8,838% | +$2.8M |
2016 Q4
4 quarters
|
|
|
BRG
2943
DELISTED
Bluerock Residential Growth REIT, Inc.
BRG
| $2.94M | ﹤0.01% |
290,856
-35,044
| -11% | -$389K |
2015 Q2
10 quarters
|
|
|
UBNK
2944
DELISTED
United Financial Bancorp, Inc.
UBNK
| $2.94M | ﹤0.01% |
166,619
+4,394
| +3% | +$80K |
2013 Q2
18 quarters
|
|
2945
Fossil Group
FOSL
$402M
| $2.93M | ﹤0.01% |
377,506
-7,098
| -2% | -$55K |
2013 Q2
18 quarters
|
|
2946
CALL
Aflac
AFL
$55.9B
| $2.93M | ﹤0.01% |
66,800
+40,000
| +149% | +$1.71M |
2017 Q3
1 quarter
|
|
|
GWR
2947
DELISTED
Genesee & Wyoming Inc.
GWR
| $2.93M | ﹤0.01% |
37,211
+22,497
| +153% | +$1.68M |
2013 Q2
18 quarters
|
|
2948
CALL
MBIA
MBI
$224M
| $2.93M | ﹤0.01% |
400,000
| – | – |
2017 Q3
1 quarter
|
|
2949
Argan
AGX
$5.39B
| $2.93M | ﹤0.01% |
65,054
+4,720
| +8% | +$281K |
2013 Q2
18 quarters
|
|
2950
ESCO Technologies
ESE
$7.13B
| $2.93M | ﹤0.01% |
48,591
+32,693
| +206% | +$1.99M |
2016 Q2
6 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2017 Portfolio in Review
As of Q4 2017, JP Morgan Chase held 5,783 positions worth $475B, up 4.7% from $453B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q4 2017 filing shows 812 new, 2,513 increased, 1,655 reduced and 342 closed positions. Its largest new stake was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $4.01B.
By sector, the portfolio is most concentrated in Miscellaneous at 22% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q4 2017 buy was Delphi Technologies PLC Ordinary Shares: 2,961,446 shares worth $155M.
- JP Morgan Chase added most to Johnson & Johnson in Q4 2017, an estimated $761M increase.
- JP Morgan Chase's biggest Q4 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $4.01B.
- JP Morgan Chase fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $275M.
- JP Morgan Chase's ten largest holdings make up 18% of its $475B portfolio in Q4 2017.
- JP Morgan Chase opened 812 new positions and closed 342 in Q4 2017.
- JP Morgan Chase's portfolio value rose 4.7% quarter-over-quarter to $475B.
Based on JP Morgan Chase's 13F filing for Q4 2017, filed 13 Feb 2018.